<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01226550</url>
  </required_header>
  <id_info>
    <org_study_id>2004.368</org_study_id>
    <nct_id>NCT01226550</nct_id>
  </id_info>
  <brief_title>Treatment of Primary Peritoneal Carcinosis of Digestive Origin Using Cytoreductive Surgery and Hyperthermic Intraoperative Peritoneal Chemotherapy With Mitomycin C and Irinotecan</brief_title>
  <official_title>Treatment of Primary Peritoneal Carcinosis of Digestive Origin Using Cytoreductive Surgery and Hyperthermic Intraoperative Peritoneal Chemotherapy With Mitomycin C and Irinotecan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open, non-randomized, phase I-II, pilot study, which evaluates the combination of&#xD;
      optimum cytoreductive surgery and hyperthermic intraoperative peritoneal chemotherapy (HIPEC)&#xD;
      with mitomycin C (MMC) and irinotecan. The latter drug will be administered in escalating&#xD;
      doses to patients with gastric, colorectal, appendicular, or primary peritoneal carcinosis&#xD;
      (PC).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Morbidity rate</measure>
    <time_frame>30 days postoperative</time_frame>
    <description>postoperative complications (class III and IV, Common Terminology Criteria V3; National Cancer Institute)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality rate</measure>
    <time_frame>30 days postoperative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraperitoneal and serumal concentration (pharmacokinetics) of mitomycine C, irinotecan, and its metabolites.</measure>
    <time_frame>per-HIPEC</time_frame>
    <description>Plasma, peritoneal, and urinary values for MMC, irinotecan, SN-38, SN-38G, APC, and NPC.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Peritoneal Carcinosis (PC)</condition>
  <arm_group>
    <arm_group_label>cytoreductive surgery and HIPEC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>cytoreductive surgery and HIPEC</intervention_name>
    <description>The most complete cytoreductive surgery possible (ideally macroscopically complete) followed by a closed-abdomen hyperthermic intraoperative peritoneal chemotherapy (HIPEC), using a closed circuit connected to the self-regulating Cavitherm machine (EEC certified). This perfusion apparatus records temperature, flow, and pressure for 90 minutes at real temperature (42-43°C).&#xD;
The dialysate is made up of peritoneal dialysis fluid containing 0.7 mg/kg of MMC and increasing doses of irinotecan added to the dialysate the last 30 minutes of the HIPEC.&#xD;
Potentiation of irinotecan using an intravenous FUFOL perfusion at least 1hour before HIPEC (1st dose level: 10 mg/m² of folinic acid, then 200 mg/m² of 5-FU; 2nd dose level: 20 mg/m² of folinic acid, then 400 mg/m² of 5-FU).</description>
    <arm_group_label>cytoreductive surgery and HIPEC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with a peritoneal carcinosis (PC) either of digestive origin or primary: a&#xD;
             colorectal or gastric carcinosis, a peritoneal pseudomyxoma or mesothelioma, or a&#xD;
             primary carcinosis of the peritoneum regardless the number of prior treatment lines.&#xD;
&#xD;
          -  A PC and primary tumor considered to be resectable according to preoperative clinical&#xD;
             and paraclinical data: absence of mesenteric retraction and absence of bladder&#xD;
             invasion.&#xD;
&#xD;
          -  Patients in good general health (ASA ≤ 2).&#xD;
&#xD;
          -  Absence of cardiorespiratory failure (PaO2 &gt; 60 mmHg in a stable condition, dyspnea ≤&#xD;
             NYHA stage 1, left ventricular ejection fraction &gt; 60%.).&#xD;
&#xD;
          -  Prothrombin level &gt;70 %, total bilirubin &lt; 2 x the normal level, ASAT and ALAT &lt; 2.5 x&#xD;
             normal levels, and alkaline phosphatases &lt; 5 x normal levels.&#xD;
&#xD;
          -  Creatinine clearance &gt; 60 ml/min, polynuclear neutrophils &gt; 1500/mm3, and a white&#xD;
             blood cell count &gt; 4000 /mm3.&#xD;
&#xD;
          -  Patients who give written, informed consent.&#xD;
&#xD;
          -  Patients affiliated with the French universal healthcare system.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with a PC with ovarian, mammary, biliary, pancreatic, or bronchial origin.&#xD;
&#xD;
          -  Evolutive patients after systemic chemotherapy.&#xD;
&#xD;
          -  Patients with a PC considered to be irresectable according to preoperative clinical&#xD;
             and paraclinical data: mesenteric retraction or bladder invasion.&#xD;
&#xD;
          -  Patients in poor general health (ASA &gt; 2).&#xD;
&#xD;
          -  Cardiorespiratory failure (dyspnea &gt; NYHA stage 1, PaO2 &lt; 60 mmHg in a stable&#xD;
             condition)&#xD;
&#xD;
          -  Prothrombin level &lt; 70 %.&#xD;
&#xD;
          -  Any brain abnormality showing on the head scan.&#xD;
&#xD;
          -  Signs of heart failure and especially left ventricular ejection fraction &lt; 60% on the&#xD;
             cardiac ultrasound.&#xD;
&#xD;
          -  Thrombocytopenia &lt; 100 000 / mm3&#xD;
&#xD;
          -  Visceral metastases other than a single resectable liver metastasis.&#xD;
&#xD;
          -  Pregnancy or breast feeding.&#xD;
&#xD;
          -  Chronic inflammatory intestinal disease and/or an intestinal obstruction.&#xD;
&#xD;
          -  History of severe hypersensitivity to irinotecan hydrochloride trihydrate or one of&#xD;
             the excipients of Campto.&#xD;
&#xD;
          -  Bilirubinemia &gt; 3 times the normal upper limit&#xD;
&#xD;
          -  Yellow fever vaccine.&#xD;
&#xD;
          -  Prophylactic treatment with phenytoin.&#xD;
&#xD;
          -  Severe medullary insufficiency.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Service de Chirurgie Générale et Thoracique, Centre Hospitalier Lyon-Sud</name>
      <address>
        <city>Pierre Bénite Cedex</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <study_first_submitted>October 20, 2010</study_first_submitted>
  <study_first_submitted_qc>October 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2010</study_first_posted>
  <last_update_submitted>December 28, 2011</last_update_submitted>
  <last_update_submitted_qc>December 28, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 30, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hyperthermic intraoperative peritoneal chemotherapy (HIPEC)</keyword>
  <keyword>Irinotecan</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>peritoneal carcinomatosis (PC)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Hyperthermia</mesh_term>
    <mesh_term>Fever</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

